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ScienceDirectIt has been reported that disseminated tumor cells (DTCs) can
be found in the majority of prostate cancer (PCa) patients, even
at the time of primary treatment with no clinical evidence of
metastatic disease. This suggests that these cells escaped the
primary tumor early in the disease and exist in a dormant state
in distant organs until they develop in some patients as overt
metastases. Understanding the mechanisms by which cancer
cells exit the primary tumor, survive the circulation, settle in a
distant organ, and exist in a quiescent state is critical to
understanding tumorigenesis, developing new prognostic
assays, and designing new therapeutic modalities to prevent
and treat clinical metastases.
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Introduction
PCa will account for about one-quarter of new cancer
diagnoses in men in 2015, with 202 800 estimated new
cases and will be the second most common cause of cancer-
related deaths in the United States with 27 540 estimated
deaths [1]. Many patients with no evidence of metastatic
disease undergo treatment for cure with surgery or radia-
tion. Unfortunately, many of these patients develop
a recurrence and ultimately succumb to their disease.
Understanding how, when, and why these patientswww.sciencedirect.com developed disseminated disease remains a high priority
for the field.
Cancer can theoretically metastasize to almost every organ
of the body and these metastases play a central role in most
cancer-related deaths. Tumor cells mainly travel to distant
sites through the blood. Important steps in haematogenous
metastasis in solid tumors include migration and invasion
of those cells from the primary tumor into the blood vessels,
circulation in the bloodstream (circulating tumor cells),
dissemination to distant sites (disseminated tumor cells),
and extravasation and eventual colonization in metastatic
niches/sites [2] (Graph 1).
Circulating tumor cells
As early as 1869, Asworth noted that cancer cells could
be found in circulating blood [3]. Although this was
almost 150 years ago, the identity and role of circulating
tumor cells (CTCs) in cancer metastasis remains un-
clear. Over the last decade, research on developing
CTCs as minimally invasive  multifunctional biomarkers
has become the ‘Holy Grail’ of the cancer community.
The detection, capture, and characterization of CTC’s
in peripheral blood as a ‘real-time liquid biopsy’ con-
tinues to be developed as an alternative to standard
biopsies. A benefit of the liquid biopsy is the fact that it
can be conducted repeatedly with low risk for side
effects, monitoring cancer progression and response to
therapy [3,4,5].
The fate of CTCs remains unclear. What percent of cells
survive transit in the blood stream to a target organ? Are
they passively sloughed into the circulation or do they
actively migrate out of the tumor? When do they start
leaving the primary tumor? What determines how fre-
quently they lodge in one distant site versus another?
This has made the characterization of disseminated tumor
cells (DTCs) critically important. Even less, however, is
known about the character of DTCs. The presence of a
DTC in a PCa patient, for example, does not necessarily
mean that he will develop a clinically evident or overt
metastasis. While it is still not possible to directly prove
that DTCs initiate metastases, there is indirect evidence
that DTC’s can develop into overt clinical metastases.
Disseminated epithelial cells are rarely found in healthy
persons/individuals, and their presence in the bone mar-
row of patients with prostate cancer significantly reduced
metastasis-free survival [6].Current Opinion in Biotechnology 2016, 40:9–15
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Overview of metastatic cascade and seeding of metastatic sites.Prostate cancer metastasis
PCa cells mainly metastasize to bone sites. The majority
of men with clinically localized PCa who develop these
bone metastases do so many years after the resection of
the primary tumor. This demonstrates a delay between
the initial treatment and the biochemical recurrence
(BCR), the first sign of future overt metastasis — suggest-
ing that cancer cells escaped early in the disease (prior to
surgery or radiation) and are able to stay dormant in the
bone marrow for years before switching to a proliferative
phenotype and eventually causing metastatic progression
[7,8]. This data makes PCa a good target to investigate
the role of DTCs in cancer dormancy and metastasis. The
questions arise, why do certain cancers recur after long
periods of time, while others remain dormant? What
happens with the DTC’s while they stay dormant and
what causes the dormant DTC’s to start proliferating?
[8,9] (Box 1).
Different types of cancer dormancy
There are many theories to explain how DTCs are kept in
a dormant state before they emerge as a clinically evident
metastasis. Cancer dormancy may be divided physiologi-
cally into ‘cellular dormancy’ or ‘tumor mass dormancy’.
The latter can be subdivided into ‘angiogenic’ and ‘im-
munologic’ dormancy. It is increasingly appreciated that
the microenvironment has an important role in conferring
and maintaining these states [10,11] ‘Cellular dormancy’
is a state in which individual cells are quiescent andCurrent Opinion in Biotechnology 2016, 40:9–15 halted in the G0 phase of the cell cycle. One of the major
causes for cancer cells to enter this type of dormancy
appears to be hypoxia of the microenvironment. Dormant
cells can re-enter the cell cycle (and thus exit the G0
arrest) and resume proliferation when the circumstances
are favorable, for instance with the addition of growth
factors, cytokines and nutrients. The second mechanism,
‘angiogenic dormancy’, is caused by the lack of angio-
genesis, and thereby nutrients, which prevent cancer cells
from proliferating. The tumor mass is kept constant and at
a limited size, due to a balance between proliferation and
apoptosis of cells. The third mechanism which can cause
dormancy is ‘immune surveillance’, where the immune
system keeps a proliferating tumor mass limited to a
constant size via persistent cytotoxic activity; that is,
‘immune-mediated dormancy’ [9,11,12] (Figure 1).
An important property of dormant DTCs as opposed to
senescent DTCs is the fact that they retain the capability
to proliferate, but that they are by definition currently not
dividing. This is determined by the lack of proliferating
markers (for example Ki-67) when DTCs are profiled at
the single-cell level. This makes them resistant to che-
motherapies targeting cell division [13,14]. Multiple other
factors in different studies are suggested to contribute to
the development of chemotherapy resistance in PCa
patients; that is, ABCG2 activation, inhibition of apopto-
sis, overexpression of P-glycoprotein and multidrug resis-
tance gene 1, and mutational alterations in the tubulinwww.sciencedirect.com
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Box 1 Important terms
Circulating tumor cell Cancer cell found in the circulation.
Dormant cell Cancer cell that remains in a quiescent state but has the potential to proliferate.
Disseminated tumor cell Cells that separated from the primary tumor and that have spread through the circulation to other
locations of the body.
Dormant disseminated tumor cell Cells that persist within foreign microenvironments; they are (reversibly) growth-arrested and they
resist targeted and cytotoxic treatment.
Minimal residual disease Tumor cells that remain after treatment, but cannot be detected by current methods in routine clinical
testing.
Micrometastasis Lesion derived from a disseminated tumor cell, that grows in another location than the primary tumor.
They are too small to be detected by current methods.
Tumor mass dormancy DTCs that are able to proliferate at the metastatic site, but due to insufficient angiogenesis and/or
active immune surveillance’ they are not able to progress to a clinically apparent metastasis.
Difference between
senescence and quiescence
Similar to senescence, quiescence is a stable, non-proliferative state, but in contrast to senescence it
reversible.gene [15]. A recent study by Hao et al. demonstrated in a
preclinical model the role of both CD44 and CD147 in the
enhancement of metastatic capacity and chemoresistance
of PCa cells. They propose that selective targeting both
factors alone or combined with docetaxel may limit PCa
metastasis and increase chemosensitivity [16].
The haematopoietic stem cells niche
Critical to understanding dormancy in the bone marrow
microenvironment is the haematopoietic stem cell niche.
The tumor microenvironment consists of many different
cell types — tumor cells, cancer stem cells (CSC), endo-
thelial cells, target organ cells, immune inflammatory
cells and fibroblasts. Studies have demonstrated that
CTC’s target the same niche in bone marrow (BM) that
houses haematopoietic stem cells (HSCs) and that DTCsFigure 1











Overview: from primary tumor to clinical metastasis.
www.sciencedirect.com co-localize with HSCs in the BM. Competition transplant
studies have demonstrated that DTCs compete directly
with HSCs for occupancy of the niche. The result of these
factors is that those ‘niche-engaged’ PCa cells are more
resistant to therapeutic intervention, either by becoming
quiescent or through other protective mechanisms of the
bone marrow environment [17,18]. Factors known to
drive and maintain haematopoietic stem cell (HSC) qui-
escence (for example, CXCR4, stem cell factor-1 (SDF-1)
and angiopoietin 1 (ANG1)) may also act on DTCs in the
bone marrow [19]. PCa cells express CXCR4, a member
of the seven-transmembrane G-protein-coupled chemo-
kine receptors. The stromal cells in the HSC niche, in
particular the osteoblasts secrete SDF-1, the ligand for
CXCR4. The migration of cancer cells and the adhesion
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12 Tissue, cell and pathway engineeringthese 2 factors. It has been shown in different studies that
inhibition of CXCR4 and application of the granulocyte-
colony stimulating factor (G-CSF) in mice releases BM-
engrafted disseminated prostate cancer cells into the
circulation, which in turn demonstrated that HSCs and
PCA cells are tethered to niches in BM by the same signal
[20,21].
A study by Taichman et al. showed earlier that the HSC
niche in the BM was able to promote cellular tumor
dormancy. They demonstrated that prostate cancer cell
lines express the growth-arrest specific 6 receptors (GAS-
6, derived from osteoblasts) Axl, Tyro3 and Mer. In vivo
studies showed that when Axl levels predominate, the
prostate cancer cells became growth arrested and
remained quiescent (in response to GAS-6), compared
to the PCa cells that express a low Axl/tyro ratio, which
were able to escape from dormancy. This study showed a
possible association of the expression ratio of Axl and
Tyro3, with the ability of PCa cells to switch between a
dormant and proliferative phenotype in the metastasis
process [22,23].
Different cell intrinsic factors and signals from the mi-
croenvironment (secreted as part of their normal activity)
are associated with an alteration of the molecular and
cellular pathways of the DTCs, which can result in a
switch between a dormant and proliferative phenotype
[24]. For example, endothelial-derived thrombospondin
1 (TSP1), bone morphogenic protein 7 (BMP7), trans-
forming growth factor-b2 (TGF-b2) and growth arrest-
specific 6 (GAS6) can mediate DTC quiescence in bone
marrow. BMP7 is a TGF-b family member and is secret-
ed by bone marrow stromal cells. This protein is capable
of inducing inhibition of ERK and p38 activation that can
induce dormancy in PCa tumor cells [12,25]. Bragoda
et al. demonstrated in a head and neck squamous cell
carcinoma model that stromal cells in the BM can produce
TGF-b1, which can upregulate the p38/ERK ratio in
DTCs, which then remain dormant. To induce cell
growth arrest, TGF-b2-induced dormancy was required;
this was achieved by TGF-b receptor 1, TGF-b receptor
III and SMAD1/5 activation. Systemic inhibition of TGF-
b receptor 1 or p38 activates dormant DTCs, which lead
to metastasis [26]. In addition, a recent patient-derived
xenograft (PDX) model, showed in vitro that cellular
adhesion of prostate cancer cells with each other and
with BM stroma activates the cells to proliferate and
promotes them to escape from dormancy. Furthermore,
global gene expression showed a downregulation of TGF-
b2 in the PCa PDX lines when proliferating, compared to
the cells that were not proliferating; thus this could be a
possible mechanism for PCa cells to escape from dorman-
cy as well [27].
In a study about the formation of bone metastatic lesions
in breast cancer (BCa) patients, an important role hasCurrent Opinion in Biotechnology 2016, 40:9–15 been found for VCAM-1, a cell adhesion molecule that
recruits osteoclast progenitors and elevates the local
osteoclast activity. They showed in a bone metastatis
dormancy model that the expression of VCAM-1 promot-
ed a metastatic outgrowth in the bone in breast cancer cell
lines [28]. Although PCa bone metastases are mostly
caused by osteoblastic activity, a study of Morrisey
et al. showed a subset of PCa bone metastases samples
obtained from rapid autopsy, a variety in osteolytic activ-
ity. Since osteoblastic and osteoclastic activities are often
coupled, this suggests that there may be an important role
of VCAM-1 for the prevention and inhibition of meta-
static recurrence in the bone of PCa patients [29]
(Figure 1).
Detection of circulating and disseminated
tumor cells
Many different assays have been developed for the de-
tection of CTCs in whole blood samples, including
microfluidic chips and methods based on size-exclusion,
red blood cell lysis, and density separation. A novel
method that does not rely on any single protein strategy
is the Epic CTC platform. With this method, all nucleat-
ed cells are retained as a blood smear on ‘sticky’ slides and
stained with fluorescent antibodies, for example, against
cytokeratins, CD45 and DAPI, and subsequently imaged
with a high definition scanner. An advantage of this
system is the capability to analyze multiple parameters
for the characterization of CTCs without enrichment [30].
Another novel non-invasive method to monitor CTCs and
tumor evolution over time, based on density separation, is
the Rarecyte system which also saves nucleated cells on
positively charged slides for analysis [31].
The only FDA-approved assay for CTC detection in
patients with metastatic breast, prostate and colon cancer
is the Cellsearch system; an immunomagnetic system for
the enumeration of circulating tumor cells of epithelial
origin. It defines a CTC according to its size, lack of the
leukocyte maker CD45, and positivity for EpCAM and
CK. The enrichment of CTCs is achieved by using immu-
nomagnetic antibodies against EpCAM [4,5,32,33].
There are no FDA-approved assays to detect DTCs,
which make it difficult to standardize detection of PCa
DTCs as the field attempts to determine the significance
of disseminated cells at the time of primary therapy [34].
CTC systems are being adapted to isolate and detect
DTCs in the BM [24]. Another technique used for the
detection of DTCs is the reverse transcriptase polymer-
ase chain reaction (RT-PCR) to detect PSA. For this
technique there is no enrichment required, due to high
reaction sensitivity. Disadvantages of this technique in-
clude lack of ‘seeing’ the DTCs (not allowing for charac-
terization) and the fact that some PCa DTCs do not
express PSA (with the result that the presence of DTCs
could be underestimated) [9].www.sciencedirect.com
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Immune-Mediated
 Dormancy
- persistent cytotoxic activity by immune cells
- lack of angiogenesis
- P38/ERK ratio increase
- Axl/Tyro3 ratio increase
- increased BMP7 expression
- increased TSP1 expression
- increased TGF-β2 expression
- decreased VCAM-1 expression
- decreased Ki-67 expression
Features of Dormancy Type:
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The different types of dormancy and potential important factors that can keep the disseminated tumor cells in a dormant state.Strategies to treat dormant disseminated
tumor cells
Given the recent data about DTCs and their role in
formation of metastases, the question arises whether it
would be better to target these DTCs while they are still
dormant. There are theoretical strategies to ‘treat’ dor-
mant DTCs. One idea is the ‘chronic dormancy mainte-
nance therapy’ to keep the dormant tumor cells
quiescent. Another strategy is the use of ‘niche-targeted
agents’ to sensitize the DTCs to cytotoxic treatment,
thereby killing the dormant DTCs. Either strategy could
result in metastasis prevention (Figure 2).
Chronic dormancy maintenance therapy
This treatment strategy could be achieved by the chronic
activation of several pathways which drive tumor cells in a
dormant state (i.e. P38) or by the use of small molecules
that mediate DTC quiescence (i.e. TSP1) [35]. Possible
drawbacks of keeping DTCs dormant include long-term
effects of chronic systemic induction of these factors on
physiologic processes in the body. TSP1 has, for example,
anti-angiogenic potential besides its anti-tumor function
[18]. Moreover, when supplementing niche-derived fac-
tors, it is still possible that dormant DTC may eventually
switch to a proliferative phenotype; so this type of treat-
ment will may give the patient a feeling of false security.
Current strategies for chronic dormancy maintenance are
only in preclinical testing.
‘Niche targeted agents’
Existing chemotherapies are not sufficient to eradicate
disseminated prostate cancer cells, once they are estab-
lished in the bone. A critical component of the ‘targeted
niche therapy’ is that agents that induce HSCs to leave
the niche also stimulate cell cycle progression [12]. If
similar agents can release PCa DTCs out of the BM
niche, then the DTCs should become more sensitivewww.sciencedirect.com to the chemotherapeutic agents that target cells in cell
cycle. In this way, DTC can be mobilized and targeted
with existing therapies. These types of niche eviction
strategies are in clinical trials.
‘Indirect targeting’
A recent clinical trial by Banys et al. in patients with breast
cancer showed that zoledronic acid (an inhibitor of osteo-
clast-mediated bone resorption) is able to contribute to
DTC eradication in the bone marrow. They propose that
the positive influence of the bisphosphonates on survival
in the adjuvant setting may be due to their effects on
DTCs. More research is needed to answer the question
whether zoledronic acid really has impact on DTCs in
PCa patients and if this treatment can maybe prevent
these patients for developing metastasis [36].
Conclusions and future perspectives
Much remains to be learned in the fields of CTCs, DTCs,
and cancer cell dormancy. In vitro models and standard-
ized methods to detect and isolate CTCs and DTCs are
needed. It appears that many autocrine and paracrine
signals are needed to induce a proliferative switch in
dormant prostate cancer DTCs. Potential treatment strat-
egies are in development to target dormant DTCs or their
environment, with the aim to keep them dormant or to
eradicate them from the BM. Since which patient will
eventually develop metastatic disease cannot be currently
predicted, it is difficult to determine which patients will
receive a benefit from targeting dormant cancer cells.
Future research must be done to determine if all early-
stage patients with detected DTCs in the BM, but with
no other signs of disease, should be treated.
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